Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

The therapy will likely face stiff competition from more convenient COVID-19 pills.

Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much

Roche Holding AG

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail

TARRYTOWN, N.Y., Nov. 15, 2021 /PRNewswire/ -- DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a global corporate responsibility leader through inclusion on the Dow Jones Sustainability World Index (DJSI World) for the third year in a row.

Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year

Regeneron Pharmaceuticals Inc. REGN, +0.73% said late Friday its board has authorized a share buyback program of up to $3 billion, saying it's an opportunity to continue to invest in the business given the "strength" of its balance sheet and business. Repurchases will be made from time to time at management's discretion, the company said.

Regeneron's board OKs $3 billion share buyback program

TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common stock.

Regeneron Announces $3 Billion Share Repurchase Program

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other countries. The authorization comes for people aged 12 years and older to treat non-hospitalized patients (outpatients) with confirmed COVID-19 who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19 and to prevent COVID-19.

Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail

Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.13% were down 0.2% in trading on Friday after the company said its monoclonal antibody cocktail has been authorized in Europe, both as a treatment and to prevent COVID-19 in cases when someone has been exposed to the virus. The cocktail is called Regen-Cov in the U.S., where it is authorized, and Ronapreve in Europe, where it can now be used in individuals who are at least 12 years old with confirmed cases of COVID-19 and who are at high risk of severe disease.

Regeneron says its COVID-19 monoclonal antibody has been authorized in Europe

TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S. and Ronapreve™ in the European Union (EU) and other countries.

Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) REGEN-COV. The casirivimab and imdevimab antibody cocktail (Ronapreve) was backed by the CHMP for treating adults and children over 12 with COVID-19 who do not require oxygen support and are at high risk of severe disease.

EU Regulator Backs Regeneron-Roche's COVID-19 Drug

TARRYTOWN, N.Y., Nov. 11, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S. and Ronapreve™ in the European Union (EU) and other countries.

CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19

Amazon

BioNTech SE

DoorDash

Johnson & Johnson

Moderna

Pfizer

AMC Entertainment

Cisco Systems

Zoom Video

More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.

10 Stocks Post-Pandemic: What to Consider, Keep and Run From

Corcept Therapeutics

Novo Nordisk

Cassava Sciences Inc

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

4 Top Biotech Stocks To Watch This Week

Investors may want to mark their calendars for Dec. 11. That's when Regeneron Pharmaceuticals Inc.'s ( REGN , Financial) shares could be driven up even further when the company updates its developing hematology portfolio at the American Society of Hematology meeting in Atlanta.

More Good News for Regeneron May Be Shared at Hematology Meeting

Bio-Techne

REGN vs. TECH: Which Stock Is the Better Value Option?

One dose of the antibody cocktail, given via four injections, cut the risk of contracting Covid-19 by over 80%.

Regeneron Says Antibody Cocktail Protects Against Covid For Up To Eight Months

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Monday said a single dose of REGEN-COV triggers long-term immunity against COVID-19. Shares of the biotech company were up more than 1.0% in premarket trading.

Regeneron Pharmaceuticals now offers long-term immunity against COVID-19

Regeneron's monoclonal antibodies grant months of protection from Covid-19, CEO Len Schleifer told CNBC on Monday.

Regeneron CEO says its monoclonal antibodies protect people from Covid for months

Amgen

Biogen

Gilead Sciences

Incyte

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals.  The new analyses show REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction during the first month after administration.

Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose

Shares of Regeneron Pharmaceuticals Inc. REGN, -5.57% gained 3.7% in premarket trading on Monday after the company said four subcutaneous injections of its monoclonal antibody treatment protected unvaccinated people from contracting COVID-19 by 81.6% for up to eight months. Four infusions of the treatment are considered one dose.

Regeneron says its COVID-19 antibody cocktail can prevent COVID-19 infections for months

TARRYTOWN, N.Y., Nov. 8, 2021 /PRNewswire/ -- Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 During the 8-month assessment period there were 0 hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group The fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without any artificial mutations or sequences Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed use of a single dose of investigational REGEN-COV® (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals.

New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

Merck

Pfizer jumped 8% Friday morning, while Moderna dropped 17.8%, Regeneron 6.2% and Merck 9%.

Billions Wiped From Covid Pharma Heavyweights—Including Moderna, Regeneron, Merck—As Pfizer's Antiviral Pill Triggers Selloff

The big biotech delivered an exceptionally strong performance in Q3.

3 Reasons Why Investors Should Love Regeneron's Q3 Update

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcript

News for Regeneron Pharmaceuticals Stock (REGN)